
may pm et
summari compani one largest world-wide provid integr dialysi servic
patient suffer chronic kidney failur
price-to-earnings oper ep
risk assess reflect stabl demand dialysi
servic driven rise senior popul
off-set depend third-parti payment
includ medicar medicaid
aug ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
see net revenu fall due
sale davita medic group
segment increas
view age popul activ
acquisit consolid environ
intern expans long-term growth
driver see expand number
dialysi facil howev expect loss
intern oper next
year think driver growth
eventu also see dialysi busi
face headwind declin payor mix
toward medicar medicaid less
profit commerci insur
forecast oper margin
invest higher labor cost
longer term margin like enhanc
oper effici leverag
expand number facil well
sale medic group segment
see ep
ep growth like aid share
repurchas program million
remain may
recommend hold
encourag medicar decis
implement rate cut multi-year period
minim disrupt provid access
patient care see substanti
regulatori risk charit assist
dialysi patient akf
previous jeopard rule
mandatori disclosur insur dialysi
provid provid charit fund
premium health plan feder court later
issu injunct suspend rule
see victori dialysi compani
view pend sale medic group
segment expect close
posit allow
focu core busi increas
financi flexibl buy-back de-lever
strateg opportun
risk recommend target price
includ failur achiev cash flow
target price appli
ev/ebitda multipl
estim multipl slight discount
peer balanc slow sale growth
outlook benefit stem sale
medic group
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview davita inc lead provid dialysi relat servic patient
suffer chronic kidney failur also known end-stag renal diseas esrd decemb
compani oper provid administr servic network outpati
dialysi center design specif outpati hemodialysi
result growth acquisit occasion becom highli leverag
opinion acquir center gambro acquisit well independ
center compani acquir center open new center sold six close
septemb acquir dsi renal ad facil led divestitur mani
dsi portfolio novemb complet merger privately-held healthcar partner
physician practic network billion payabl billion cash million share
decemb enter agreement sell davita medic group collabor
hold subsidiari billion cash sale expect close
improv compani financi flexibl
hemodialysi use artifici kidney call dialyz remov certain toxin fluid salt
patient blood togeth machin control extern blood flow monitor certain vital sign
patient periton dialysi use patient periton abdomin caviti elimin fluid
market profil esrd state advanc renal impair irrevers requir routin
dialysi treatment kidney transplant sustain life treatment option esrd includ
hemodialysi periton dialysi kidney transplant growth procedur driven
age popul increas incid rate diseas caus kidney failur
diabet hypertens lower mortal rate dialysi patient growth rate minor
popul higher-than-averag incid rate esrd assum dialysi market
 continu grow mid-singl digit rang next sever year age
popul keep long-term growth mid-singl digit rang
legal/regulatori issu govern medicar medicaid remain primari
payor care esrd dialysi patient account roughli two-third dialysi revenu
medicar account major govern revenu balanc deriv
commerci payor esrd payment rate dialysi establish congress medicar composit
rate set center medicar medicaid servic includ payment dialysi
treatment suppli use treatment specifi laboratori test certain pharmaceut
provid paid separ servic pharmaceut includ erythropoietin epo
vitamin analog iron supplement gener averag cost servic pharmaceut
plu small margin base price set medicar medicar payment rate suffici
cover averag cost provid dialysi treatment
cover treatment medicar pay amount set medicar system patient
respons remain case secondari payor cover part
financi trend averag revenu per treatment
level volatil recent year due fluctuat patient mix
commerci govern insur patient go forward expect revenu growth mid-
upper singl digit ep growth low-doubl digit expand oper
domest intern address medicar reimburs cut may berkshir
hathaway took stake agre standstil agreement acquir
stake decemb berkshir stake septemb
complet stock split rais number share outstand million
offic intern
presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
gather suffici number vote
pass variou repeal replac bill
republican success elimin
individu mandat passag
tax cut job act decemb
see develop neg
health care servic provid given fewer
custom choos enrol insur
year date march
versu increas
composit index health
servic index increas vs
increas composit
fundament outlook health care
servic sub-industri next month
neutral think servic includ
rehabilit clinic laboratori
dialysi continu benefit
favor demograph partli offset
increas pressur reduc govern
spend rais possibl medicar
reimburs rate cut possibl
repeal elimin medicaid
expans trump administr
becom neutral dialysi group
view favor patient demograph
off-set reimburs rate pressur
center medicar medicaid servic look
cut expens expect provid see
higher treatment margin due lower drug
cost util howev think
provid still reliant maintain
commerci base rate much
higher offer medicar think
age popul increas focu
prevent care benefit clinic lab
think increas test per requisit
well esoter test lead
remain posit pharmaci benefit manag
pbm see pbm benefit
billion dollar brand drug slate
lose patent protect come year
increas gener drug usag would increas
profit pbm
expect republican administr
continu effort repeal
servic sub-industri larg exposur
medicaid clientel could advers
uncompens care rate could rise
hospit facil would lead
lower profit lower demand health
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
growth medic group segment expect sale growth
volum growth partial off-set declin revenu per treatment
rais target ev/ebitda
multipl estim discount peer reflect
slower revenu growth outlook trim ep
estim report oper
ep vs consensu sale increas
increas treatment volum see sale growth
impact reimburs rate pressur given limit
visibl due regulatori uncertainti surround futur
maintain hold opinion /k snyder
et capit iq maintain hold opinion share
inc keep target
ep estim multipl discount three-year
histor averag price-to-earnings reflect expect modest margin
compress higher cost cut ep estim
set report oper ep
vs capit iq consensu net revenu increas
driven growth medic group expect signific declin
number dialysi patient cover due soft overal
enrol exchang /k snyder
inc rais target
appli ev/ebitda multipl estim
multipl line peer reflect reimburs rate concern
keep ep estim cut
announc enter six year suppli agreement
inc replac prior agreement set expir
end also issu initi guidanc call
declin oper incom vs guidanc kidney segment flat
incom davita medic group /k snyder
analyst research note compani news
et cfra maintain hold opinion share inc
keep target price appli ev/ebitda
multipl estim slight discount peer averag
reflect slow revenu growth outlook regulatori headwind rais
ep estim trim
report oper ep vs consensu
revenu increas aid increas number treatment
per day growth revenu per treatment see oper margin
expand driven pend sale davita medic group
segment expect declin sale due segment sale
growth modest increas volum revenu per treatment
rais target price appli
ev/ebitda multipl estim line peer
balanc reimburs rate pressur expect benefit
sale medic group segment increas ep estim
set report oper ep
vs line consensu sale increas aid
growth treatment per day expect experi margin pressur
driven increas labor cost flat reimburs rate /keith
et cfra keep buy opinion share group
agre acquir davita medic group physician
group believ deal fit well
strategi expand optum unit includ primari
urgent ambulatori care davita medic oper clinic urgent
care center half-dozen outpati surgic center medic staff
six state see million patient note unit post
loss think leverag overlap certain area
includ cost synergi improv unit profit /jeffrey
et cfra keep hold opinion share inc
enter definit agreement
sell davita medic group dmg segment billion cash dmg
oper nearli clinic well urgent care center six
outpati surgic center pend transact subject regulatori
approv customari close condit expect close
see pend deal posit allow focu
core kidney dialysi busi increas financi flexibl
buyback de-lever strateg opportun /danni yang
maintain target price appli ev/ebitda
multipl estim line peer balanc
stabl sale growth outlook expect margin compress lower
reimburs rate partial off-set cost reduct effort trim
ep estim
report oper ep vs consensu
sale increas growth medic segment expect
sale growth aid modest volum increas /keith snyder
keep target appli ev/ebitda multipl
estim slight discount five-year
histor averag reflect slow long-term sale earn
growth outlook keep ep estim trim
report oper ep
vs consensu total sale increas driven
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
